8 results about "Monobody" patented technology

The present disclosure relates to pharmaceutical and diagnostic compositions comprising macropinocytosis-selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain linked to a pharmaceutically active or diagnostic moiety. The present disclosure also relates to methods of treatment and diagnosis comprising administering to a subject in need thereof a pharmaceutical composition described herein. TIFF2023551388000007.tif63166

The present application relates to an Intercellular Adhesion Molecule 2 (ICAM-2) binding polypeptide. This ICAM-2 binding polypeptide comprises a fibronectin type III (FN3) domain having at least one modified loop amino acid sequence and, optionally, a modified beta strand. The one or more modified loop sequences, together with the optional beta strand modifications, enable selective binding to ICAM-2. Also disclosed are conjugates that include the ICAM-2 binding polypeptide, polynucleotides encoding the same, and methods of using these materials for inhibiting transplant organ rejection as well as treatment of hypertension and cancer.

The present invention provides a novel substance that stably binds to a surface protein expressed on NK cells. The present invention provides a monobody that binds to a surface protein of an NK cell, wherein the monobody has an amino acid sequence of any one of (1) to (3): (1) an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12; (2) an amino acid sequence given by deletion, substitution, and / or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acids; and (3) an amino acid sequence having an identity of 80% or more with an amino acid sequence represented by any one of SEQ ID NOs: A1 to A12 excluding arbitrary amino acid sequences, wherein X1, X2, X3, X4, X5, and X6 in SEQ ID NOs: A1 to A12 each independently represent an arbitrary amino acid, and n1, n2, n3, n4, n5, and n6 each independently represent an arbitrary natural number.X1n1 X2n2 X3n3 (SEQ ID NO: A1)PIWGRYGTTVRGQTYYWWMLX1n1X2n2 X3n3 (SEQ ID NO: A2)WTWLGYEYYWWDSKPGAIGIX1n1 X2n2 X3n3 (SEQ ID NO: A3)TYWDWGFRWSWARRTHISWFX4n4X5n5 X6n6 (SEQ ID NO: A4)PGYYMWQRGVINGQERAYGHPEHFX4n4X5n5 X6n6 (SEQ ID NO: A5)RYKYHRRINGTQWYVFNEAGDVAGYX1n1X2n2 X3n3 (SEQ ID NO: A6)GPIVSYSWWYHWVGYVNEKYDAWQSYVQX1n1X2n2 X3n3 (SEQ ID NO: A7)QAYWFEYTWWLEVVYDDQWTSGX4n4X5n5 X6n6 (SEQ ID NO: A8)TSPWYNGYDQYKSWNLEEFHX4n4X5n5 X6n6 (SEQ ID NO: A9)TPPWIHKGWVTPYGRKWVGMNGWX1n1X2n2 X3n3 (SEQ ID NO: A10)LWHYYGDQYWWMYVPEYYFNPWX1n1X2n2 X3n3 (SEQ ID NO: A11)TDRNYDITYGMQYWWDGYSYSEEAWYYX4n4X5n5 X6n6 (SEQ ID NO: A12)WSWESYWHGTYTFMKDIPSYY

Fusion Protein compositions comprising masked IFNs and methods of making masked IFNs are disclosed herein. Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease.

The present invention relates to a monobody-based chimeric antigen receptor. The monobody-based chimeric antigen receptor comprises an extracellular ligand binding domain including a monobody. In addition, the present invention relates to an immune cell having the monobody-based chimeric antigen receptor expressed on the cell surface membrane thereof. The monobody-based CAR-immune cell: 1) can exhibit excellent effects in preventing or treating cancer by targeting a receptor expressed on the surface of a cancer cell; 2) uses human FN3-based monobodies as extracellular ligand binding domains unlike animal-derived scFv-based CAR-immune cells, thereby exhibiting low immunogenicity when administered to humans; 3) has a smaller size than scFv, thereby providing higher tissue penetration capability; 4) can minimize side effects (e.g. occurrence of autoimmune diseases due to non-specific binding) associated with conventional antibody therapies for cancer treatment; and 5) enables various monobody-based CAR-immune cells to be produced by using already-established monobody libraries for various cancer cell antigens. Accordingly, the present invention can be usefully employed in preventing or treating intractable solid tumors having various antigens

The present invention relates to a novel fusion protein in which a monobody specifically bidning to a tumor antigen is linked to L-asparaginase for treating solid cancer more efficiently, and a use thereof, paticularly to a novel fusion protein comprising a recombinant monobody which specifically binds to clareticulin and an L-asparaginase linked to the C-terminus of the recombinant monobody, wherein the recombinant monobody has a peptide that specifically binds to the calreticulin inserted into at least one of the BC loop and the FG loop of human fibronectin domain III (Fn3) as an asparaginase-based novel anticancer agent targeting tumor antigen whose drug delivery efficacy to tumor tissue is enhanced.

The present disclosure is directed to pharmaceutical and diagnostic compositions comprising macropinocytosis selective non-binding protein-drug conjugates. These non-binding protein-drug conjugates comprise a non-binding fibronectin type III (FN3) domain coupled to a pharmaceutically active moiety or a diagnostic moiety. The disclosure is also directed to methods of treatment and diagnosis that involve administering the pharmaceutical compositions described herein to a subject in need.